Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
  • Research & Development
    • Our Focus
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Complement-Mediated Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
  • Research & Development
    • Our Focus
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Complement-Mediated Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter

Contact Us


Office Locations

USA Office
PO Box 1045
125 S King Street, Suite 2A
Jackson WY 83001-1045.
T: +1 (307) 699-6012
e-mail: info (at) amyndas.com
              clinicaltrials (at) amyndas.com
investors (at) amyndas.com
@Amyndas

EU Office
27 Kyprou
Glyfada 16675
GREECE
T: +30 (694) 722-1847
e-mail: info (at) amyndas.com

 

Latest News

  • Iatronet.gr: Φάρμακο με ελληνική “υπογραφή” για τη γεωγραφική ατροφία ωχράς κηλίδας

  • EUSTM (9th Congress): Novel Transformative Treatment for Periodontal Disease

  • Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

  • Review: Compstatins: the dawn of clinical C3-targeted complement inhibition

 

Latest Publications

  • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

  • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

  • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

  • Complement as a target in COVID-19?

 
 

Copyright © 2025 - Amyndas Pharmaceuticals. All Rights Reserved. Designed by WPZOOM